A Phase 1 Open-label, Uncontrolled, Non-randomized, Maximal Use Pharmacokinetic Study to Evaluate the Systemic Exposure and Safety of KX2-391 Ointment 1% When Applied to 25 cm2 of the Face or Balding Scalp in Subjects With Actinic Keratosis
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2019
Price : $35 *
At a glance
- Drugs Tirbanibulin (Primary)
- Indications Actinic keratosis
- Focus Pharmacokinetics
- Sponsors Athenex
- 06 Dec 2019 Status changed from recruiting to completed.
- 20 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Aug 2019.
- 20 Nov 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Apr 2019.